Thrombocytosis differential diagnosis: Difference between revisions

	Thrombocytosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Thrombocytosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Thrombocytosis differential diagnosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Thrombocytosis differential diagnosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Thrombocytosis differential diagnosis
CDC on Thrombocytosis differential diagnosis
Thrombocytosis differential diagnosis in the news
Blogs on Thrombocytosis differential diagnosis
Directions to Hospitals Treating Thrombocytosis
Risk calculators and risk factors for Thrombocytosis differential diagnosis

VisualWikitext

Revision as of 15:24, 28 August 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]

Overview

Thrombocytosis Differential Diagnosis

Differentiating the diseases that can cause thrombocytosis :

Category	Condition		Etiology	Mechanism			Inherited	Acquried	Clinical manifestations									Para−clinical findings									Gold standard	Associated findings
									Demography	History	Symptoms			Signs				Para−clinical findings
											Symptoms			Signs				Lab Findings								Imaging
											Fever	Rash	Bleeding	BP	Splenomegaly	Jaundice	Other	CBC			PBS	Bone marrow exam	PT	PTT	UA
				Increased megakaryocyte proliferation	Accelerated platelet release	Reduced platelet turnover					Fever	Rash	Bleeding	BP	Splenomegaly	Jaundice	Other	Plt	HB	WBC	PBS	Bone marrow exam	PT	PTT	UA
Autonomous thrombocytosis	Hematologic malignancies	Essential thrombocythemia	Acquired mutation of JAK2, CALR, or MPL	+	-	-	-	+				Flushing					Erythromelalgia	↑										Thrombo-hemorrhagic complications
		Polycythemia vera	Acquired mutation of JAK2	+	-	-	-	+			-	Flushing	-	Nl	+	-	Erythromelalgia Pruritus	↑										Thrombo-hemorrhagic complications
		Primary myelofibrosis	Bone marrow fibrosis Mutation in JAK2, CALR, or MPL	+	-	-	-	+										↑										Thrombo-hemorrhagic complications
		Chronic myeloid leukemia	Translocation (9;22), the Philadelphia chromosome BCR-ABL1 oncogene	+	-	-	-	+							+	-		↑	↑		Immature leukocytes Leukemic blasts Leukoerythroblastic features Giant platelets							Increase of immature myeloid cells
		Acute myeloid leukemia		+	-	-	-	+										↑			Leukemic blasts Leukoerythroblastic features Giant platelets
		Myelodysplastic syndromes^[1]	Unknown Mutation	+	-	-	-/+	+	Elderly	Exposure to Chemotherapy Radiation therapy Tobacco smoke	+/-	Petechiae, purpura, diffuse erythematous rash	+	Nl	+	+	Shortness of breath Fatigue	↑/↓	↓	↓	Large platelets Ovalomacrocytosis Basophilic stippling Howell-Jolly body Pelger-Huet anomaly Ring sideroblasts	Impaired myeloid maturation Dyserythropoiesis Dysgranulopoiesis Dysmegakaryocytopoiesis Hypercellular bone marrow Fibrosis	Nl	Nl	Nl	NA	Bone marrow examination + clinical manifestation	Thrombosis at unusual sites Thrombosis in younger patients Might transformed to acute leukemia
	Familial thrombocytosis		Mutation in TPO and MPL	+	-	-	+	-										↑	Nl	Nl	Giant platelets Platelet conglomerates Bizarre forms Megakaryocytic fragments Platelet hypogranularity							Mendelian inheritance High penetrance Polyclonal hematopoiesis
Category	Condition		Etiology	Increased megakaryocyte proliferation	Accelerated platelet release	Reduced platelet turnover	Inherited	Acquried	Demography	History	Fever	Rash	Bleeding	BP	Splenomegaly	Jaundice	Other signs	Plt	HB	WBC	PBS	Bone marrow exam	PT	PTT	UA	Imaging	Gold standard	Associated findings
Reactive thrombocytosis	Anemia/ blood loss	Iron deficiency Blood loss Hemolysis		+						History of bleeding or iron deficiency								↑	↓									Required iron studies
	Infection	Chronic infections		+	+													↑		↑
		Tuberculosis		+	+													↑		↑
		Acute bacterial and viral infections		+	+													↑		↑
	Inflammation	Vasculitides		+	+													↑		↑
		Acute pancreatitis		+	+													↑		↑
		Malignancy		+	+													↑		↑
	Condition		Etiology	Increased megakaryocyte proliferation	Accelerated platelet release	Reduced platelet turnover	Inherited	Acquried	Demography	History	Fever	Rash	Bleeding	BP	Splenomegaly	Jaundice	Other signs	Plt	HB	WBC	PBS	Bone marrow exam	PT	PTT	UA	Imaging	Gold standard	Associated findings
	Tissue damage	Thermal burns																↑
		Trauma																↑
		Myocardial infarction																↑
	Medication	Myelosuppressive agents																↑
		Vincristine																↑
		Epinephrine, glucocorticoids																↑
		Interleukin-1B																↑
		All-trans retinoic acid																↑
		Thrombopoietin																↑
	Other	Post-splenectomy or functional asplenia				+				Prior surgical removal of the spleen Sickle cell disease								↑			Howell-Jolly bodies Nucleated RBCs
		Allergic reactions																↑
		Exercise																↑
	Pseudothrombocytosis	Mixed cryoglobulinemia
	Pseudothrombocytosis	Cytoplasmic fragments
Category	Condition		Etiology	Increased megakaryocyte proliferation	Accelerated platelet release	Reduced platelet turnover	Inherited	Acquried	Demography	History	Fever	Rash	Bleeding	BP	Splenomegaly	Jaundice	Other signs	Plt	HB	WBC	PBS	Bone marrow exam	PT	PTT	UA	Imaging	Gold standard	Associated findings

References

↑ Natelson, Ethan A.; Pyatt, David (2013). "Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog". Advances in Hematology. 2013: 1–11. doi:10.1155/2013/309637. ISSN 1687-9104.

[NatelsonPyatt2013-1] Natelson, Ethan A.; Pyatt, David (2013). "Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog". Advances in Hematology. 2013: 1–11. doi:10.1155/2013/309637. ISSN 1687-9104.

[1]

@@ Line 52: / Line 52: @@
 ! rowspan="7" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Autonomous thrombocytosis
 ! rowspan="6" align="center" style="background:#DCDCDC;" |Hematologic malignancies
-! align="center" style="background:#DCDCDC;" |Essential thrombocythemia
+! align="center" style="background:#DCDCDC;" |[[Essential thrombocytosis|Essential thrombocythemia]]
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+* Acquired mutation of ''JAK2, CALR,'' or ''MPL''
+| align="center" style="background:#F5F5F5;" + | +
+| align="center" style="background:#F5F5F5;" + | -
+| align="center" style="background:#F5F5F5;" + | -
+| align="center" style="background:#F5F5F5;" + | -
+| align="center" style="background:#F5F5F5;" + | +
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |Flushing
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 69: / Line 69: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+* Erythromelalgia
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 79: / Line 81: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+* Thrombo-hemorrhagic complications
 |-
-! align="center" style="background:#DCDCDC;" |Polycythemia vera
+! align="center" style="background:#DCDCDC;" |[[Polycythemia vera]]
 | align="center" style="background:#F5F5F5;" + |
+* Acquired mutation of ''JAK2''
+| align="center" style="background:#F5F5F5;" + | +
+| align="center" style="background:#F5F5F5;" + | -
+| align="center" style="background:#F5F5F5;" + | -
+| align="center" style="background:#F5F5F5;" + | -
+| align="center" style="background:#F5F5F5;" + | +
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + | -
+| align="center" style="background:#F5F5F5;" + |Flushing
+| align="center" style="background:#F5F5F5;" + | -
+| align="center" style="background:#F5F5F5;" + |Nl
+| align="center" style="background:#F5F5F5;" + | +
+| align="center" style="background:#F5F5F5;" + | -
 | align="center" style="background:#F5F5F5;" + |
+* Erythromelalgia
+* Pruritus
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 95: / Line 113: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+* Thrombo-hemorrhagic complications
+|-
+! align="center" style="background:#DCDCDC;" |[[Myelofibrosis|Primary myelofibrosis]]
 | align="center" style="background:#F5F5F5;" + |
+* Bone marrow fibrosis
+* Mutation in ''JAK2, CALR'', or ''MPL''
+| align="center" style="background:#F5F5F5;" + | +
+| align="center" style="background:#F5F5F5;" + | -
+| align="center" style="background:#F5F5F5;" + | -
+| align="center" style="background:#F5F5F5;" + | -
+| align="center" style="background:#F5F5F5;" + | +
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 105: / Line 133: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-|-
-! align="center" style="background:#DCDCDC;" |Primary myelofibrosis
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 118: / Line 144: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+* Thrombo-hemorrhagic complications
+|-
+! align="center" style="background:#DCDCDC;" |[[Chronic myelogenous leukemia|Chronic myeloid leukemia]]
 | align="center" style="background:#F5F5F5;" + |
+* Translocation (9;22), the Philadelphia chromosome
+* ''BCR-ABL1'' oncogene
+| align="center" style="background:#F5F5F5;" + | +
+| align="center" style="background:#F5F5F5;" + | -
+| align="center" style="background:#F5F5F5;" + | -
+| align="center" style="background:#F5F5F5;" + | -
+| align="center" style="background:#F5F5F5;" + | +
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 125: / Line 161: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + | +
+| align="center" style="background:#F5F5F5;" + | -
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+* Immature leukocytes
+* Leukemic blasts
+* Leukoerythroblastic features
+* Giant platelets
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 135: / Line 179: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+* Increase of immature myeloid cells
+*
 |-
-! align="center" style="background:#DCDCDC;" |Chronic myeloid leukemia
+! align="center" style="background:#DCDCDC;" + |[[Acute myeloid leukemia]]
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + | +
+| align="center" style="background:#F5F5F5;" + | -
+| align="center" style="background:#F5F5F5;" + | -
+| align="center" style="background:#F5F5F5;" + | -
+| align="center" style="background:#F5F5F5;" + | +
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 153: / Line 198: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+* Leukemic blasts
+* Leukoerythroblastic features
+* Giant platelets
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 178: / Line 227: @@
 * [[Radiation therapy]]
 * [[Tobacco smoking|Tobacco smoke]]
-| align="center" style="background:#F5F5F5;" + | +
+| align="center" style="background:#F5F5F5;" + | +/-
 | align="center" style="background:#F5F5F5;" + |[[Petechia|Petechiae]], [[purpura]], diffuse erythematous rash
 | align="center" style="background:#F5F5F5;" + | +
@@ Line 184: / Line 233: @@
 | align="center" style="background:#F5F5F5;" + | +
 | align="center" style="background:#F5F5F5;" + | +
-| align="center" style="background:#F5F5F5;" + |[[Shortness of breath]], [[fatigue]]
+| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |↓
+* [[Shortness of breath]]
+* [[Fatigue]]
+| align="center" style="background:#F5F5F5;" + |↑/↓
 | align="center" style="background:#F5F5F5;" + |↓
 | align="center" style="background:#F5F5F5;" + |↓
 | align="center" style="background:#F5F5F5;" + |
+* Large platelets
 * Ovalomacrocytosis
 * Basophilic stippling
 * [[Howell-Jolly body]]
-* Dysplastic [[Neutrophil|neutrophils]]
+* Pelger-Huet anomaly
+* Ring sideroblasts
 | align="center" style="background:#F5F5F5;" + |
 * Impaired [[myeloid]] maturation
@@ Line 206: / Line 259: @@
 | align="center" style="background:#F5F5F5;" + |[[Bone marrow examination]] + clinical manifestation
 | align="center" style="background:#F5F5F5;" + |
+* [[Thrombosis]] at unusual sites
+* Thrombosis in younger patients
 * Might transformed to [[acute leukemia]]
-|-
-! align="center" style="background:#DCDCDC;" + |Acute myeloid leukemia
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
 |-
 ! colspan="2" align="center" style="background:#DCDCDC;" |Familial thrombocytosis
 | align="center" style="background:#F5F5F5;" + |
+* Mutation in TPO and MPL
+| align="center" style="background:#F5F5F5;" + | +
+| align="center" style="background:#F5F5F5;" + | -
+| align="center" style="background:#F5F5F5;" + | -
+| align="center" style="background:#F5F5F5;" + | +
+| align="center" style="background:#F5F5F5;" + | -
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 247: / Line 280: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
+| align="center" style="background:#F5F5F5;" + |Nl
+| align="center" style="background:#F5F5F5;" + |Nl
 | align="center" style="background:#F5F5F5;" + |
+* Giant platelets
+* Platelet conglomerates
+* Bizarre forms
+* Megakaryocytic fragments
+* Platelet hypogranularity
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 255: / Line 296: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+* Mendelian inheritance
-| align="center" style="background:#F5F5F5;" + |
+* High penetrance
-| align="center" style="background:#F5F5F5;" + |
+* Polyclonal hematopoiesis
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
 |-
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
 ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
-! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Decreased platelet production
+! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Increased megakaryocyte proliferation
-! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in blood
+! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Accelerated platelet release
-! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in spleen
+! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Reduced platelet turnover
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
@@ Line 301: / Line 337: @@
 * Hemolysis
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + | +
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 307: / Line 344: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+* History of bleeding or iron deficiency
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 314: / Line 352: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
+| align="center" style="background:#F5F5F5;" + |↓
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 323: / Line 363: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+* Required iron studies
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
 |-
 ! rowspan="3" align="center" style="background:#DCDCDC;" |Infection
 ! align="center" style="background:#DCDCDC;" |Chronic infections
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + | +
+| align="center" style="background:#F5F5F5;" + | +
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 342: / Line 382: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 358: / Line 396: @@
 ! align="center" style="background:#DCDCDC;" + |Tuberculosis
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + | +
+| align="center" style="background:#F5F5F5;" + | +
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 370: / Line 410: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 386: / Line 424: @@
 ! align="center" style="background:#DCDCDC;" + |Acute bacterial and viral infections
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + | +
+| align="center" style="background:#F5F5F5;" + | +
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 398: / Line 438: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 415: / Line 453: @@
 ! align="center" style="background:#DCDCDC;" |Vasculitides
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + | +
+| align="center" style="background:#F5F5F5;" + | +
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 427: / Line 467: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 443: / Line 481: @@
 ! align="center" style="background:#DCDCDC;" + |Acute pancreatitis
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + | +
+| align="center" style="background:#F5F5F5;" + | +
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 455: / Line 495: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 471: / Line 509: @@
 ! align="center" style="background:#DCDCDC;" |Malignancy
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + | +
+| align="center" style="background:#F5F5F5;" + | +
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 483: / Line 523: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 499: / Line 537: @@
 ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
-! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Decreased platelet production
+! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Increased megakaryocyte proliferation
-! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in blood
+! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Accelerated platelet release
-! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in spleen
+! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Reduced platelet turnover
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried
@@ Line 542: / Line 580: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 570: / Line 608: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 598: / Line 636: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 627: / Line 665: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 655: / Line 693: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 683: / Line 721: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 711: / Line 749: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 739: / Line 777: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 767: / Line 805: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 784: / Line 822: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + | +
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+* Prior surgical removal of the spleen
+* [[Sickle-cell disease|Sickle cell disease]]
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 795: / Line 836: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+* Howell-Jolly bodies
-| align="center" style="background:#F5F5F5;" + |
+* Nucleated RBCs
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 824: / Line 866: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 852: / Line 894: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
+| align="center" style="background:#F5F5F5;" + |↑
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
@@ Line 862: / Line 905: @@
 | align="center" style="background:#F5F5F5;" + |
 | align="center" style="background:#F5F5F5;" + |
-| align="center" style="background:#F5F5F5;" + |
+|-
+! rowspan="2" |
+! rowspan="2" |Pseudothrombocytosis
+!'''[[Cryoglobulinemia|Mixed cryoglobulinemia]]'''
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+|-
+!'''Cytoplasmic fragments'''
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
+!
 |-
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
 ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
-! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Decreased platelet production
+! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Increased megakaryocyte proliferation
-! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in blood
+! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Accelerated platelet release
-! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Platelet destruction in spleen
+! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Reduced platelet turnover
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited
 ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquried

Thrombocytosis differential diagnosis: Difference between revisions

Revision as of 15:24, 28 August 2018

Overview

Thrombocytosis Differential Diagnosis

References

Navigation menu